Role of the Immunogenic and Tolerogenic Subsets of Dendritic Cells in Multiple Sclerosis

Zhong-Xiang Xie,1 Hong-Liang Zhang,1,2 Xiu-Juan Wu,1 Jie Zhu,1,2 Di-Hui Ma,1 and Tao Jin1

1Neuroscience Center, Department of Neurology, The First Hospital of Jilin University, Changchun 130021, China
2Department of Neurobiology, Care Sciences and Society, Karolinska Institute, 141 86 Stockholm, Sweden

Correspondence should be addressed to Di-Hui Ma; madihui@263.net and Tao Jin; drtao.jin@hotmail.com

Received 24 August 2014; Revised 1 January 2015; Accepted 1 January 2015

Academic Editor: Fumio Tsuji

Copyright © 2015 Zhong-Xiang Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Multiple sclerosis (MS) is an immune-mediated disorder in the central nervous system (CNS) characterized by inflammation and demyelination as well as axonal and neuronal degeneration. By effective therapies to reverse the disease are still lacking; most therapeutic drugs can only ameliorate the symptoms or reduce the frequency of relapse. Dendritic cells (DCs) are professional antigen presenting cells (APCs) that are key players in both mediating immune responses and inducing immune tolerance. Increasing evidence indicates that DCs contribute to the pathogenesis of MS and might provide an avenue for therapeutic intervention. Here, we summarize the immunogenic and tolerogenic roles of DCs in MS and review medicinal drugs that may affect functions of DCs and have been applied in clinic for MS treatment. We also describe potential therapeutic molecules that can target DCs by inducing anti-inflammatory cytokines and inhibiting proinflammatory cytokines in MS.

1. Introduction

Multiple sclerosis (MS) is an autoimmune disease in the central nervous system (CNS) that is characterized by inflammation and demyelination as well as axonal and neuronal degeneration [1]. Plenty of immune cells participate in the pathogenesis of MS, which include dendritic cells (DCs), natural killer cells, B cells, and macrophages. DCs are professional antigen presenting cells (APCs) which are of great importance in mediating immune responses by providing signaling transduction for naive T cells to differentiate into myelin-reactive T cells. The latter are responsible for demyelination in CNS, one of the main pathological features of MS. To date, there has been no cure for MS. Current therapeutic strategies are focused on reducing the incidence of relapse and on alleviating the symptoms of the disease. Indeed, most of the therapeutic compounds and molecules at present are immune modulators or inhibitors which may have an effect on DCs. As DCs play an important role in immune tolerance, tolerogenic DCs may be induced to deal with MS relapses. Here, we summarize the effects of the different therapeutic compounds and molecules on DCs in MS. Specifically, we describe compounds that can both induce tolerogenic DCs and reduce MS occurrence and relapses. We also mention several potential therapies for MS that target DCs by inducing anti-inflammatory cytokines and inhibiting proinflammatory cytokine production.

2. Dendritic Cell Subsets and Biological Function

DCs are ubiquitous in the body. There are two major subsets of DCs: conventional DCs (cDCs; also known as myeloid dendritic cells (mDCs)) and plasmacytoid DCs (pDCs) [2], as shown in Table 1. In mouse, conventional DCs express both CD11c and MHCII and can be further subdivided into two major subsets based on the expression of CD8α: CD8α (+) DC and CD8α (−) DC [3, 4]. The former induces Th1 type responses while the latter drives Th2 type responses [5, 6]. However, human’s cDCs are lack of expression of CD8α and are labeled based on other markers, namely, CD11c and...
HLA-DR, CD11c can be further subdivided into three subsets: CD1c+ (BDCA-1), CD141+ (BDCA-3), and CD16+DCs based on the expression of distinct cell surface markers [7]. CD16+DCs are considered to be a subset of both DCs and monocytes, because of their expressions of CD1c+ (BDCA-1) and CD141+ (BDCA-3) [8]. CD1c+DCs and CD141+DCs have been extensively studied for their unique gene expression profiles and special functions [9]. For example, CD141+DCs are located in human lymph nodes, bone marrow, tonsil, blood, and spleen [9, 10] with high expression of toll-like receptor 3 (TLR3) and IL-12p70 and IFN-β secretion [11]. Like their functional murine counterpart CD8α+DC subset, they induce Th1 responses and cross-present exogenous antigen [8]. CD1c+DCs, in turn, express most of the TLRs including the extracellular TLRs (TLR1, TLR2, TLR4, TLR5, and TLR6) and the endosomal TLRs (TLR3 and TLR8) [11]. When activated with TLR agonists, CD1c+DCs secrete high level of IL-8 but low level of TNF-α, IL-6, CCL3 (MIP-α), and CCL4 (MIP-β), indicating the strong inflammatory activity [7]. When CD1c+DCs were stimulated with *Escherichia coli*, high levels of anti-inflammatory cytokine IL-10 and regulatory molecules indoleamine 2, 3-dioxygenase (IDO) as well as soluble CD25 were produced. Moreover, *E. coli*-activated CD1c+DCs suppressed T-cell proliferation in an IL-10-dependent manner [12].

pDCs can be found in both lymphoid and nonlymphoid organs. Unlike cDCs, pDCs do not express CD11c, but HLA-DR, CD123, BDCA-2(CD303), and BDCA-4 (CD304), which can be used as markers to isolate pDCs [13]. Through TLR7 and TLR9, pDCs could recognize viral DNA or RNA and secrete large amounts of type I interferons (IFN) [14]. pDCs can also secrete moderate amounts of TNF-α and IL-6 upon viral stimulation. The former serve to either promote the maturation of pDCs in an autocrine manner or mediate immune response while the latter mediate immune responses by inducing plasma cell differentiation and immunoglobulin secretion [15, 16]. Some researchers divide human pDCs into two subsets: pDC1 and pDC2 [17]. The pDC1 expresses high level of CD123 and low level of CD86 and TLR2; in addition, it secretes IFN-α and induces IL-10 producing T cells [17]. The pDC2, in turn, is characterized by low CD123 expression and a high level of CD86 and TLR2 [17]. Moreover, they are the main source of plasma IL-6 and IL-12 and mediate the differentiation of naive T cells into Th17 cells [17].

Under the steady state, pDCs display an immature phenotype with a very limited capability to induce naïve T cell activation [18]. Upon activated through either IL-3 or virus CpG oligonucleotides, pDCs differentiate into mature DCs and can form stable connections with T cells [19], which significantly enhance their capacity to activate these lymphocytes [15]. pDCs are also involved in immune tolerance with the potential to induce T regulatory cells (Tregs) and upregulate expression of IDO when they are exposed to a TLR9 agonist and activated [20]. Specifically, mature pDCs upregulate the expression of inducible co-stimulator ligand (ICOS-L) and induce differentiation of naïve T cells into IL-10 secreting Tregs [21].

Tolerogenic DCs are generally viewed as a steady state semimature DCs which can express costimulatory molecules but did not produce proinflammatory cytokines. They can efficiently induce Tregs instead of inducing Th1/Th17 responses [22]. Both tolerogenic DCs and immature DCs would induce Tregs, but the difference between tolerogenic DCs and immature DCs is that the former are more stable than the latter. In vivo, after being exposed to the inflammatory microenvironment tolerogenic DCs will change much less than immature DCs [23]. Tolerogenic DC would be induced *in vitro* by modulating DCs with cytokines and drugs (e.g., IL-10 and VD3). Recently, researchers have found a new subset of tolerogenic DC: DC-10. In peripheral blood, DC-10 is characterized by HLA-G expression and IL-10 secretion and is essential in promoting and maintaining tolerance via induction of Tregs [24]. This discovery provides us new perspective for autoimmune disease treatment.

Tolerogenic DCs bear several characteristics: low expressions of costimulatory molecules (CD80, CD86, and CD40) and high levels of surface molecules (PDL1 and CD95L) which are involved in T-cell inhibition [25]. Low levels of costimulatory molecules contribute to T cell anergy, as T cells cannot receive the secondary signals for stimulation. However, the high levels of suppressive cytokines, such as IL-10, suppress the immune response. Alternatively, tolerogenic DCs can induce the development of CD4+FoxP3+ Tregs and type 1 regulatory T cells (Tr1), which can secrete both IL-10 and TGF-β. Tregs in the CNS can downregulate the immune response by secreting IL-10, thereby inducing anergy or inhibiting the T cell effector response [26]. As previously described, tolerogenic DCs express IDO which catalyzes...
Figure 1: Tolerogenic dendritic cells play their tolerogenic role through promote regulatory T cells differentiation. The tolerogenic DCs regulate autoreactive T cells by inducing anergy, apoptosis, phenotypically skewing, and/or Treg cells or tolerogenic DCs can be induced through the induction of T regulatory cells, such as Tr1 and CD4+, CD25+, and Foxp3 cells.

Tryptophan either resulting in depletion of the microenvironment, or consequently inhibiting the proliferation of T-cells [27]. Taken together, tolerogenic DCs regulate autoreactive T cells by inducing anergy, apoptosis, phenotypically skewing, and/or Treg cells [28, 29] (Figure 1). The therapeutic potentials of tolerogenic DCs in EAE, an animal model of MS, have been further reviewed [30].

3. Dendritic Cells in the Central Nervous System

As previously described, DCs are ubiquitous in the body including the CNS. Although it is difficult to find DCs in healthy CNS parenchyma due to the immune privilege, DCs have been isolated from vascular-rich compartment, that is, the choroid plexus and the meninges [31, 32]. In addition, cDCs and pDCs can also be isolated from the cerebrospinal fluid (CSF) of healthy individuals [33]. Interestingly, a recent study reported that DCs can also be found in the brain parenchyma near the vessels (juxtavascular) [34], which challenged the traditional concept that DCs reside only in the perivascular space. However, the source of the DCs in the CNS remains unclear thus far. Some studies in vitro showed that the resident microglia in the CNS could differentiate into DCs in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) [35, 36]. Cytokines including IL-6 and TNF-α can induce DC differentiation in the CNS as well [37]. Moreover, DCs in the brain may originate from the periphery, and it has been found that Fms-like tyrosine kinase 3 ligand (Flt3L) can induce the proliferation of DCs [38] and recruit pDCs to the brain parenchyma [39]. Using the criterion of Flt3-dependent development, Anandasabapathy and colleagues found that DCs in the meninges and choroid plexus of a healthy mouse brain exhibited differentiation and antigen presenting program similar to spleen DCs while being distinct from microglia, indicating that DCs in a healthy brain possibly arise from pre-DCs which enter the brain perivascular region [40].

Besides, the juxtavascular locations of DCs [34] also provide indirect evidence suggesting the brain DCs are not derived from the brain tissue but from a vascular source.

4. Role of Dendritic Cells in MS

4.1. MS Introduction. Multiple sclerosis (MS) is a multifactorial autoimmune disorder of the CNS characterized by chronic inflammatory demyelination with hallmark of focal infiltration and accumulation of immune cells resulted in the subsequent damage to the myelin and axons [41]. Based on the clinical data and the histopathological studies, four clinical subtypes of MS have been identified, including relapsing-remitting MS (RRMS), primary progressive MS (PPMS), secondary progressive MS (SPMS), and progressive relapsing MS (PRMS), among which the RRMS accounts for approximately 85% of all MS cases [41]. Demyelination and axonal loss are two characteristics of MS. Demyelination and axonal loss are closely influenced although it remains controversial regarding the causal relationship. Currently, "the inside-out model" and "the outside-in model" are two competing hypotheses of MS etiology. The outside-in model refers to demyelination caused axonal loss and neurodegeneration, while the inside-out model believes that neural and axonal damage is caused by demyelination [42]. Experimental autoimmune encephalomyelitis (EAE) is the traditional animal model of MS. In EAE, mice were immunized with myelin specific antigen, the antibodies and autoreactive T cells are against myelin itself or oligodendrocyte, and axons damage developed from myelin (outside) to axons (inside) [43]. Mice immunized with neurofilament light (NF-L) protein bear axonal degeneration and gray matter inflammation with mild demyelination, which is representative of the inside-out model [44]. Besides, Theiler's murine encephalomyelitis virus- (TMEV-) induced demyelination disease (TMEV-IDD) is a viral model for MS. In TMEV infection the lesion developing from the axons (inside) to the myelin (outside) is also an inside-out model [44]. In patients...
with MS, evidence exists to support both “the inside-out model” and “the outside-in model” [43]. Some neurologists hence argue that MS may be an unrecognized primary degenerative disorder and consider noninflammatory PPMS as the real MS, with inflammatory forms reflecting secondary host's aberrant immune responses [45]. Although MS was considered to be predominantly a T cell-mediated disease, emerging evidence indicates that DCs play a crucial role in the pathology of MS. As natural immunomodulators and professional APCs, DCs serve as an orchestrator to preserve the balance between immunity and tolerance due to their unique ability to stimulate naive T cells. Upon pathological activation by DCs in the periphery, the myelin-reactive T cells secrete proinflammatory cytokines which aid their entry through the endothelial blood-brain barrier (BBB) to the CNS. These myelin-reactive T cells are then reactivated upon encounter of resident APCs including DCs, presenting myelin-derived epitopes. Subsequently, these perivascular T cells will secrete proinflammatory cytokines which recruit other inflammatory cells. Consequently, this will lead to demyelination of axons accounting for the sensory and motor deficits of MS.

4.2. DCs in Animal Model of MS. Autoreactive CD4+ T cells, including Th1 and Th17 cells, are essential in the pathogenesis of experimental autoimmune encephalomyelitis (EAE). Specifically, the autoreactive CD4+ T cells in the CNS can damage the neuronal axon leading to MS [48] (Figure 3). In peripheral lymphoid nodes, DCs can activate self-antigen specific naïve CD4+ T cells and subsequently promote them to differentiate into Th1 and Th17 effector cells [47]. At this point, DCs in the perivascular space of the CNS can reactivate autoreactive T cells in the vicinity and facilitate their infiltration into the parenchyma of the CNS [49]. cDCs are sufficient to activate encephalitogenic T cells in both EAE and TMEV-IDD [50, 51]. However, depletion of cDCs did not affect the activation of encephalitogenic Th1 and Th17 cells in EAE [22]. Taken together, these data suggest that although DCs are sufficient to prime EAE, other APCs were also needed.

Tregs have a crucial tolerogenic effect on EAE. Depletion of Tregs in the brain worsened the severity of EAE, while passive transfer of CNS derived Tregs seemed protective [52]. Mice with EAE showed upregulated levels of Treg cells and improved disease prognosis after being injected with DCs, which expressed myelin oligodendrocyte glycoprotein (MOG) and TNF-related apoptosis-inducing ligand (TRAIL) on cell surface [53]. Of note is that depletion of DCs in mice would worsen EAE, DCs are responsible for the upregulation of PD-1 on antigen-specific T cells and subsequently induce the de novo conversion of Treg cells from naïve T cells during immune responses [54]. PD-1 and PD-L1 mRNA expression were elevated on BMDCs from TMEV-IDD mice. Moreover,
Figure 3: Dendritic cells (DCs) promote the differentiation of Th1 and Th17 cells. Mature DCs could induce the differentiation of naïve CD4+ T cells into different types of T helper (Th) cells. Both Th1 and Th17 cells play pathogenic roles in the disease progression of MS mainly through their cytokines.

TMEV-IDD mice treated with PD-1 antibody exhibit more severe clinical presentation, indicating PD-1 pathway plays a pivotal regulatory role in the development of TMEV-IDD [55].

pDCs have been evidenced to have an immunosuppressive role in EAE. During the acute and relapsing phases of EAE, depletion of pDCs enhanced pathogenic CNS CD4+ T cell activation as well as IL-17 and IFN-γ production [56]. DCs can also function as APCs to promote the expansion of myelin-Ag-specific natural Tregs [57]. These natural Tregs suppress the autoimmune T cell response and thus confer a natural protection against EAE [57]. In sum, DCs play both pathogenic and regulatory role in MS model.

4.3. DCs Phenotype and Function Change in MS. DCs, including cDCs and pDCs, were abundant in the inflamed CNS lesions and CSF of patients with MS. Additionally, circulating DCs, which secrete high levels of proinflammatory cytokines, are elevated in MS [58]. Thus, levels of DCs in the CSF of MS patients are considered to be a clinically relevant marker for MS [59]. At the early stage of MS, the number of DCs in the demyelinating lesions of CNS is increased [60]. The expression of CD40 on cDCs from both RRMS and SPMS is higher compared with controls [61], while cDCs of patients with PPMS express lower levels of costimulatory molecules like CD80 and CD86 [62]. In patients with SPMS, cDCs showed a proinflammatory profile in which the expression of CD80 is elevated, PD-L1 is decreased, and the secretion of proinflammatory cytokines including IL-12 and TNF-α is also elevated [61]. Further investigations showed that cDCs from SPMS only induced a polarized Th1 response, while cDCs from RRMS induced higher levels of Th1 (IFN-γ, TNF-α) and Th2 (IL-4, IL-13) cytokines compared with controls [61]. cDCs of patients with MS may produce elevated amounts of IL-23 compared with healthy controls [63]. Besides, the expression of chemokine (C-C motif) receptor 5 (CCR5) on cDCs was upregulated in both blood and CSF of patients with MS [33]. Interestingly, CCR5 ligands chemokine (C-C motif) ligand 3 (CCL3) and CCL5 are increased in plaques of patients with MS, providing a possible explanation that recruitment of cDCs to the inflamed CNS may be related to this pathway [64]. In summary, cDCs of patients with MS manifest a proinflammatory phenotype which would be critical in the pathogenesis of MS.

In patients with MS, pDCs can be found in CSF, in lesion plagues, and also in leptomeninges [33, 65]. pDCs would increase in CSF of untreated patients during relapse and this may be explained by either a virus infection or a downregulatory process [66]. In MS patients, the phenotype and function of pDCs would be affected. The expression of CD86 and 4-IBBL was significantly lower on pDCs from MS patients than from controls [67]. And when stimulated with CD40L or IL-3, pDCs from MS patients showed impaired maturation ability; the upregulation of CD86, 4-IBBL, CD40, and CD83 was inhibited [67]. In RRMS patients, the expression of CCR7 on pDCs was upregulated compared with healthy controls [68]. The pDC1 expresses a high level of CD123 and a low level of CD86 and TLR2; in addition, it secretes IFN-α and induces IL-10 producing T cells [17]. The pDC2, in turn, is characterized by low CD123 expression and high levels of CD86 and TLR2 [17]. Moreover, pDC2 are the main source of plasma IL-6 and IL-12 and mediates the differentiation of naïve T cells into Th17 cells [17]. pDCs in MS have a lower pDC1/pDC2 ratio in the peripheral blood, denoting that pDCs in MS patients have a proinflammatory profile [17].

Beside the phenotype change of pDCs in MS, the cytokines secretion of pDCs was also affected. In patients with MS, upon stimulation with CpG, pDCs from PBMC have a significantly lower IFN-α secretion than in controls [67]. Moreover, pDCs from MS lost the capacity to induce proliferation and IFN-γ secretion of allogeneic lymphocytes [67].

5. Therapeutic Options for MS

So far there has been no cure for MS. Current therapeutic compounds mainly lessen the symptoms and reduce the frequency of relapse. The effects of therapeutic compounds on MS by affecting DCs are listed in Table 2.
Table 2: Effects of current therapeutic options on DCs in multiple sclerosis.

| Drugs                  | Subset and quantity of DCs | Cytokines secreted | Surface markers |
|------------------------|---------------------------|--------------------|-----------------|
| **Corticosteroids**    | pDC\[^\d\]* | IL-12\[^\d\]* | CCR7\[^\d\]* |
|                        | cDC\[^\d\]* | IL-1\[^\d\]* | MMP-9\[^\d\]* |
| **Interferon-\(\beta\)** | cDC\[^\d\]* | IL-23\[^\d\]* | MHC-II\[^\d\]* |
|                        | IL-12\[^\d\]* | BDCA-2\[^\d\]* | |
|                        | IL-1\[^\d\]* | MMP-9\[^\d\]* | |
|                        | IL-23\[^\d\]* | MHC-II\[^\d\]* | |
|                        | IL-1\[^\d\]* | MMP-9\[^\d\]* | |
|                        | IL-23\[^\d\]* | BDCA-2\[^\d\]* | |
| **Glatiramer acetate** | pDC\[^\d\]* | IL-10\[^\d\]* | CD83\[^\d\]* |
|                        | pDC\[^\d\]* | IL-27\[^\d\]* | B7-H1\[^\d\]* |
| **Natalizumab**        | CD209+DC\[^\d\]* | IL-17\[^\d\]* | HLA-DR\[^\d\]* |
|                        | IL-12\[^\d\]* | ROR-\(\gamma\)\[^\d\]* | CD86\[^\d\]* |
|                        | IL-10\[^\d\]* | MIP-1\[^\d\]* | CD40\[^\d\]* |
|                        | IL-10\[^\d\]* | IP-10\[^\d\]* | 4-IBBL\[^\d\]* |
| **Fingolimod**         | IL-12\[^\d\]* | IL-10\[^\d\]* | VLA-4\[^\d\]* |
| **Teriflunomide**      | IL-6\[^\d\]* | IL-10\[^\d\]* | |
| **Dimethyl fumarate**  | IL-12\[^\d\]* | IL-10\[^\d\]* | |
| **Laquinimod\[^\d\]* | CD1c+DC\[^\d\]* | IL-12\[^\d\]* | |
|                        | CD303+DC\[^\d\]* | IL-1\[^\d\]* | |
| **Daclizumab\[^\d\]* | IL-10\[^\d\]* | TNF-\(\alpha\)\[^\d\]* | |

\[^\d\]* indicates that laquinimod and daclizumab are under phase III clinical trial.

5.1. Corticosteroids. Corticosteroids are most effective during the acute phase of MS relapses. Intravenous methylprednisolone (MP) treatment accelerates the clinical recovery in acute MS relapse, but the mechanism or the effect on DCs is not well understood. After a short-term treatment with IVMP, pDCs and cDCs in the peripheral blood significantly decreased, while Tregs increased, indicating that the immunosuppressive effect of MP may be related to decreased numbers of circulating DCs and increased Tregs [69]. Moreover, circulating pDCs decreased after corticosteroid therapy and then are increased again during the remission period, that is, 30 days after treatment was completed [70]. Therefore, DCs may exert their therapeutic effects on partly through decreasing the number of pathogenic DCs.

5.2. Interferon-\(\beta\). Interferon- (IFN-) \(\beta\) is an immunomodulatory cytokine and is used as another therapeutic compound against RRMS. The mechanism, however, remains incompletely clear. The effect of IFN-\(\beta\) on DCs is very complex. IFN-\(\beta\) could affect the secretion of cytokines from DCs. It has been found that DCs from MS patients secrete low levels of IL-12p70 and high levels of IL-10 after IFN-\(\beta\) therapy [71]. And IFN-\(\beta\) inhibits IL-12p70 secretion by mature DCs but enhances IL-12p70 secretion by immature DCs. IFN-\(\beta\) can as well counteract the IL-12-enhancing effect of IFN-\(\gamma\) on DCs irrespective of their maturation status [72]. Zhang et al. found that IFN-\(\beta\) plays a crucial role in inhibiting Th17 response through affecting DCs, because human-derived DCs treated with IFN-\(\beta\) may upregulate the expression of TLR7, reduce IL-1\[^\d\]* and IL-23, and increase IL-27, all of which could inhibit Th17 differentiation [73]. Moreover, IFN-\(\beta\) may inhibit IL-1\[^\d\]*, IL-23, and TGF-\(\beta\) and induce secretion of IL-27, IL-12, and IL-10, all of which contribute to the suppression of Th17 cell differentiation. In sum, IFN-\(\beta\) has a therapeutic value for RRMS [41]. Among other cytokines, IL-27 plays a unique role in IFN-\(\beta\) treatment for MS. Sweeney and colleagues found that IFN-\(\beta\) induced IL-27 both in vitro and in vivo. Additionally, IL-27 induced by IFN-\(\beta\) was associated...
with response to IFN-β therapy in MS patients. This finding indicates that the therapeutic role of IFN-β in MS is partly mediated through IL-27 [74].

IFN-β may also affect the maturation of DCs in MS. The in vitro experiments showed that when monocytes derived DCs at different stages of maturity were stimulated with IFN-β, the development of DCs was inhibited only at the early stage of maturity [75]. In MS patients treated with IFN-β, the function and phenotype of pDCs were evaluated before and during the treatment. And the results exhibited that the expression of MHC-II and BDCA-2 molecules were decreased, while the expression of costimulatory molecules such as CD83 and B7H1 were upregulated [65]. B7H1 (PD-L1), a member of B7 family proteins with the ability to inhibit CD4 T-cell activation expressed on DCs, was also upregulated in vitro in MS patients [76]. Besides, IFN-β also has the capacity to inhibit DC migration via inhibiting the expression of CCR7 and matrix metalloproteinase-(MMP-)9 proteins in mature DCs, which consequently reduces DCs migratory capacity [77] and impaired the antigen presentation role of DCs, and enhancing their anti-inflammatory abilities.

IFN-β therapy in MS can change the subtype and numbers of DCs. RRMS patients treated with IFN-β were found with decreased number of circulating DCs [62]. MS patients were even found to be in a reversed ratio of pDC1/pDC2 in peripheral blood (4.4:1 in healthy controls versus 0.69:1 in MS patients). In addition, IFN-β treatment increased the pDC2 cells in vivo, which reconstituted the disturbed balance [17]. Apart from its influence on the subset and quantity of pDCs, IFN-β could reduce the level of processed TLR9 protein of pDCs from MS patients. This would decrease activation of pDCs by viral pathogens and might hinder the relapse of MS [17]. Besides, IFN-β upregulate the expression of glucocorticoid-induced tumor necrosis factor receptor ligand (GITRL) on DCs, and the increased GITRL consequently enhances the proliferation of Tregs through the ligation of GITR [78]. Meanwhile, IFN-β depresses the expression of CTLA-4 on Treg cells, thus promoting Treg cells stimulation [78]. Interestingly, a recent study showed that there were 60 abnormal genes expressed on pDCs in MS patients, while the expression pattern was normalized after IFN-β therapy [79].

In conclusion, IFN-β induce anti-inflammatory cytokines secretion and inhibit proinflammatory cytokines secretion by DCs. IFN-β decrease the costimulatory molecule and chemokine molecules expression on DCs; through this way IFN-β may inhibit T cell activation and release the infiltration of T cells in CNS. Besides, IFN-β upregulate the expression of GITAL on DCs which would induce the proliferation of Tregs.

5.3. Glatiramer Acetate. Glatiramer acetate (GA), which is a mixture of synthetic polypeptides comprising four amino acids, has been widely used for treating RRMS. GA is an analog of myelin basic protein (MBP) with the potential to compete with MBP for MHC binding. GA functions by inducing GA-specific T cells which shift T cell balance from a dominant proinflammatory phenotype (Th1/Th17) to an anti-inflammatory phenotype (Th2/Treg) [80]. The therapeutic potential of GA in MS is related to its effects on DCs. GA can modulate the secretion of cytokines by DCs. In vitro, GA reduces IL-12 secretion from DCs in MS patients [81]. Vieira et al. reported that GA inhibited the production of Th1 polarizing factor IL-12p70 and induces the production of anti-inflammatory cytokine IL-10 from DCs [82]. Moreover, GA interfered with expression of osteopontin, IL-17, and RAR-related orphan receptor gamma (RORγt) in DCs of mice with EAE; therefore, biased DCs shift into an anti-inflammatory phenotype [83]. GA not only biased DCs towards the anti-inflammatory phenotype, but also affected their penetration through the BBB during neuroinflammation in EAE. GA could suppress the expression of molecules that affect the BBB penetration during neuroinflammation [83].

GA reduced the HLA-DR expression of DCs both in vitro and in vivo. [84]. pDCs from MS patients exhibited a significantly lower level of CD86 and 4-IBBL, and GA treatment partially restored the phenotype and function of pDCs in MS [67]. Additionally, MS patients treated with GA had lower levels of CD40 on DCs, which was associated with a lower risk of relapse in MS [85]. Besides, GA can enhance NK cells lysis of both immature DCs and mature DCs. CD86 and NKp30 are important for NK cell lysis of immature DCs, whereas CD80, CD83, HLA-DR, and HLA-I are important for lysis of mature DCs [86].

In summary, GA biased DCs toward anti-inflammatory phenotype and GA inhibit CD40 expression on DCs and thus lower the relapse risk of MS. The enhancement of NK lysis of DCs by GA may have an indirect effect for its therapeutic role on MS.

5.4. Natalizumab. Natalizumab is a monoclonal antibody for treating MS. It could block the very late antigen 4 (VLA-4), which is widely expressed on leukocytes and associated with the infiltration of leukocytes into the CNS. Natalizumab is effective against a number of APCs in the CNS. For example, the expression of MHC-II molecules and the number of CD209+DCs are significantly decreased in cerebral perivascular space of the natalizumab treated MS patients [87]. Natalizumab therapy may result in lower expression of VLA-4 on both pDCs and cDCs of MS patients. Besides, in vitro coculture experiments showed that natalizumab not only downregulated the expression of VLA-4, but also reduced the ability of DCs in stimulating the antigen-specific T-lymphocyte response [88]. Above all, although natalizumab mainly limits the infiltration of lymphocytes within CNS, its capacity to reduce VLA-4 on DCs may limit DCs infiltration in CNS and this capacity would be of utmost importance in the treatment of MS.

5.5. Fingolimod. Fingolimod (FTY720), a sphingosine analog, is the first oral drug for treating RRMS, which was approved by the US Food and Drug Administration in September 2010 [89, 90]. In vivo, the drug binds to four out of the five sphingosine-1-phosphate (SIP) receptors after phosphorylation (FTY720-p) [91]. After the combination, FTY720 downmodulates SIP receptor expression on lymphocytes, slows the outflow of lymphocytes from secondary lymph organs and limits lymphocytes infiltration within the CNS [92].
In vitro, DCs treated with FTLY720/FTLY720-P impaired the chemotaxis and immunostimulatory capacity of DCs [92]. IL-12 secretion was reduced while IL-10 production was increased when mature DCs were treated with FTLY720/FTLY720-P. Similarly, T cells cultured in the presence of FTLY720 or FTLY720-P treated DCs showed an altered cytokine production profile which indicated a shift from Th1 toward Th2 differentiation [92]. In vivo, FTLY720 modulates the traffic of DCs by reducing their capacity of migration to transendothelial [93]. A study indicated that FTLY720 inhibited IL-12p70 secretion by DCs and macrophages while increasing IL-10 production in DCs [94]. Briefly, FTLY720 may exert its immunosuppressive roles partly by modulation of DC trafficking. Although FTLY720 impaired the chemotaxis and immunostimulatory capacity of DCs in vitro, it remains to study to what extent DCs are influenced by FTLY720 treatment.

5.6. Immunosuppressive Drugs in MS Treatment. Several immunosuppressive drugs have been approved for treating MS patients, such as mitoxantrone and azathioprine. Some of these drugs play their immunosuppressive role through influencing the functions of DCs.

5.6.1. Mitoxantrone. Mitoxantrone was initially used as an antineoplastic agent. In the United States, it has been approved for treating MS, including secondary-progressive MS, progressive-relapsing MS, and worsening RRMS [95]. In vitro, mitoxantrone at low concentrations reduces the antigen presenting capability of DCs and apoptosis of DCs, whereas at higher concentrations it causes cell lysis [96]. Mitoxantrone exerts its cytotoxic and immunomodulatory effects on microglia in CNS. It can induce apoptosis of microglia by upregulating IL-10 and downregulating IL-23p19 secretion of microglia [97]. However, the specific effect of mitoxantrone on DCs remains to be elucidated.

5.6.2. Azathioprine. Azathioprine (Aza) is another immunosuppressive drug that is commonly used in organ transplantation. It can also be used to treat autoimmune disorders such as MS. 6-Mercaptopurine (6-MP) is the active form of Aza. 6-MP is able to inhibit DC activation and induce the differentiation of DCs into a less immunogenic phenotype in vitro. Moreover, 6-MP significantly reduced the secretion of IL-23 and the expression of CCR7 on DCs while increasing the expression of IL-10 [98]. These findings indicate that Aza has a therapeutic role in MS via both immunosuppressive and immunomodulatory pathways.

In conclusion, immunosuppressive drugs including mitoxantrone and azathioprine would affect the function of DCs in vitro, but in vivo it remains to be studied to what extent DCs are influenced by this treatment.

5.7. New Drugs. Several new drugs show potential therapeutic effects on MS. Some of the drugs have been approved for the treatment of MS, while the others are still under clinical trials. Here, we summarize drugs that have direct or indirect effects on DCs.

5.7.1. Teriflunomide. Teriflunomide is a newly approved oral drug for RRMS [99]. As a new oral medicine for MS, teriflunomide can reduce relapses and slow disability progression and its side effects are mild and transitory [100]. What is more, recently studies showed that teriflunomide has beneficial effects for patients with early MS [101]. Teriflunomide is an inhibitor of dihydro-orotate dehydrogenase (DHODH), which inhibits the proliferation of stimulated T and B cells, decreasing the number of lymphocytes infiltration within CNS [102]. In vitro, teriflunomide decreases the secretion of proinflammatory cytokines IL-6, IL-8 and monocyte chemotactic protein-1 (MCP-1) in activated PBMC [103]. There was also research demonstrating that teriflunomide impaired Th1 differentiation and induce Th2 differentiation [104]. Teriflunomide did not impair LPS-induced maturation of DC, and the ability of mature DC to induce allogenic T cell responses was not affected [105]. Further study about teriflunomide on DC should be conducted in the future.

5.7.2. Dimethyl Fumarate (DMF). Dimethyl fumarate (DMF) is the third oral drug used for RRMS; it was approved by FDA in March, 2013 [106]. DMF and its primary metabolite monomethyl fumarate (MMF) have neuroprotective effects. DMF and MMF protect neurons and astrocytes against oxidative stress-induced cellular injury and loss; they exert the role mainly through upregulation of nuclear factor-erythroid-derived 2-like (Nrf2) dependent antioxidant response [107]. DMF affect the function of DCs. Through suppression of both NF-κB and extracellular signal-regulated kinases 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1), DMF inhibit DCs maturation and Th1 and Th17 differentiation [108]. Moreover, DMF treatment in human induces IL-4 producing Th2 cells and generates DCs that produce IL-10 instead of IL-12 and IL-23 [109]. In mice, DMF also generates such DCs that may induce Th2 cell differentiation in vitro and protect mice from EAE in vivo. The underlying mechanism has been explained as DMF resulting in glutathione (GSH) depletion and HO-1 induction phosphorylation. HO-1 prevents transcription of the IL-23p19, whereas signal transducers and activators of transcription (STAT) 1 inactivation inhibit transcription of the IL-12p35 [109]. This research indicated that DMF may play an important part in inhibiting Th1 and Th17, which are critical in the pathologies of MS.

5.7.3. Laquinimod. Laquinimod is a novel oral drug that is under evaluation for the treatment for RRMS. Laquinimod exerts its immunomodulatory role through multiple ways. In mice, laquinimod inhibits peripheral proinflammatory T cells into CNS [110]. In vitro, laquinimod decreases the secretion of proinflammatory cytokines and increases the secretion of anti-inflammatory cytokines from PBMC [110]. Jolivel et al. exhibited that the beneficial effect of laquinimod for MS mainly mediated by DCs. The authors found that human monocyte-derived matured DCs treated with laquinimod had reduced capacity to induce CD4+ T cell proliferation and proinflammatory cytokines secretion [111]. What is more, chemokine productions by both murine and human matured DCs were reduced when DCs were treated
with laquinimod [111]. In laquinimod-treated patients, the chemokine and cytokine secretions were reduced in CD1c+ matured DCs, and the number of conventional CD1c+ and plasmacytoid CD303+DCs was decreased within peripheral blood mononuclear cells [111]. Moreover, in laquinimod treated DCs, expression of CD86 was inhibited. The authors believed that the inhibition of the NF-kB pathway was responsible for the changes of dendritic cell maturation and functions [111]. A placebo-controlled phase III study showed that laquinimod treatment reduced disability progression and had a modest effect on annualized relapse rate [112]. A recent phase III study showed that laquinimod may reduce (at least in the initial phase of treatment) some of the more destructive pathological processes in patients with RRMS [113]. Another study showed that although once-daily oral laquinimod resulted in statistically nonsignificant reductions in ARR and disability progression, there were significant reductions in brain atrophy versus placebo [114].

5.7.4. Daclizumab. Daclizumab, which blocks the interaction of CD25 with IL-2 and has been approved for renal transplant rejection, is a mAb specific for CD25 (α subunit of IL-2 receptor) [115]. Subcutaneous daclizumab high-yield process (HYP) administered every 4 weeks led to clinically significant reductions in brain atrophy versus placebo [114]. The mechanism of action of daclizumab for MS has been summarized in a recently published review [117]. Multiple immune cells are affected by daclizumab including natural killing cells (NK cells) and DCs. Human monocyte-derived DCs treated with daclizumab would change the cytokines secretion by DCs [118]. Proinflammatory cytokines such as IL-12, IL-1, TNF-α, IL-6, and IFN-γ production decreased and anti-inflammatory cytokines IL-10 increased [118]. Besides, the ability of DCs to prime allogenic T cells diminished, while the upregulation of costimulatory surface markers on DCs induced upon LPS stimulation was not affected [118]. Activated DCs could express IL-2Rα subunit and secrete IL-2; IL-2Rα subunit expressed on DCs captures IL-2 and forms a complex with the IL-2Rβ and γc subunits expressed on the T-cell surface [117, 119]. Daclizumab also blocks presentation of IL-2 and inhibit T cell activation and proliferation [117, 120]. Above all, daclizumab exerts its therapeutic role partly via converting DCs functions toward a tolerogenic profile.

5.7.5. Alemtuzumab. Alemtuzumab is a mAb against CD52. CD52 is a surface molecule on T and B lymphocytes, NK cells, DCs, and most monocytes [121]. Alemtuzumab can deplete CD52 bearing cells and has been approved for the treatment of chronic B cell lymphocytic leukemia. Alemtuzumab can also improve relapse rate versus interferon beta-la in patients with MS who were treatment-naïve (CAMMS223 and CARE-MS I) or had relapsed on prior therapy (CARE-MS II), to reduce sustained accumulation of disability (CAMMS223 and CARE-MS II) [122]. Although alemtuzumab would cause some side effects such as serious infections, infusion-associated reactions, or even autoimmune events, safety monitoring program allowed for early detection and management of autoimmune events [122]. In US and Europe alemtuzumab has been submitted for licensing in RRMS. In May 2014, the UK National Institute of Health and Care Excellence (NICE) recommended alemtuzumab as an option for the treatment of RRMS [123]. So far, effects of alemtuzumab on RRMS have not been found associated with DCs, while in previous studies alemtuzumab did affect the function of DCs. It is believed that alemtuzumab may deplete monocyte-derived DCs and its precursors [124]. CD52 is expressed on peripheral blood DCs but not on tissue DCs. Administration of alemtuzumab to patients with lymphoproliferative disorders resulted in circulating DCs reduction [125]. Analysis of monocyte-derived DCs in vitro showed the activation-induced maturation with lipopolysaccharide was lost [125]. Not only did alemtuzumab affect the quantity of DCs, but the phenotype of DCs was also changed. Alemtuzumab in patient with renal transplant caused reduction of the total number of peripheral DCs and a significant shift from myeloid to plasmacytoid DC subsets (mDC/pDC ratio) [126]. In sum, alemtuzumab depletes DCs which may be one of its main mechanisms in the treatment of RRMS.

5.7.6. Secukinumab. Secukinumab is a mAb against IL-17A, also called SECU or AIN457. A phase II clinical study has been conducted to determine the efficacy and tolerance of AIN457, which revealed that AIN457 appeared to be superior to placebo and a majority of patients with RRMS tolerated it well [127, 128].

5.7.7. MOR103. MOR103 is a mAb that may neutralize GM-CSF. GM-CSF stimulates activation, maturation, and differentiation of macrophages, monocytes, neutrophils, eosinophils, DCs, and microglia [128]. In EAE, blockade of GM-CSF led to reduced microglial activation [129]. A randomized, double-blind, placebo-controlled phase Ib study to evaluate the safety and pharmacokinetics of MOR103 has been completed. The results are accessible online while conclusions are yet to be reached (https://clinicaltrials.gov/ct2/show/results/NCT01517282?term=NCT01517282&rank=1&sect=X40156).

5.7.8. Anti-IL12/23p40 Antibodies (ABT-847). Both IL-12 and IL-23 are proinflammatory cytokines secreted by APCs. IL-12 and IL-23 have the common subunit IL-12/23p40. Anti-IL-12/23p40 antibody significantly ameliorated EAE in rodents [130, 131] and non-human primates [132, 133]. Unfortunately, clinical trials in phases I and II using anti-IL-12/23p40 antibodies (ustekinumab) in MS patients received conflicting results [134, 135]. ABT-874 is another monoclonal anti-IL-12/23 antibody, which exhibits similar safety in ustekinumab patients whereas efficacy for disease is lacking [136].

6. Dendritic Cells as a New Target for MS Treatment

The current treatment options for MS can affect DC function and phenotype. Although there is no DC-based drug for MS, there are multiple DC-based immunotherapies for EAE,
a traditional animal model of MS. Tolerogenic DCs can be induced by multiple pathways. As previously described, tolerogenic DCs are able to induce periphery tolerance and alleviate the symptom of MS/EAE. These tolerogenic DCs have the therapeutic potentials for MS.

6.1. Estrogen. The relapse incidence of MS patients is lower during pregnancy, which suggests that estrogen may have a great effect on the pathogenesis of MS (Table 3). The following reports indicate that estrogen has immune modulation abilities. Murine treatment with estrogen decreased or even diminished EAE clinical symptoms [137,138]. Further studies showed that the inhibition of estrogen on EAE was associated with DCs function [139]. Mice treated with estrogen have lower frequency of DCs migrating into the CNS of EAE [139]; the frequency of DCs producing IFN-γ and TNF-α was also reduced in spleens of EAE mice treated with estrogen [139]. Mature DCs treated with estrogen had a lower capacity for antigen presentation; moreover, secretion of proinflammatory cytokines was also inhibited in vitro [139,140]. However, estrogen does not affect the expression of costimulatory molecules on DCs. Estrogen activates DCs and induces the expression of IDO, which inhibits T cell responses and reduces the production of both Th1 and Th2 cytokines [141]. In addition, DCs treated with estrogen (estrogen-DCs) showed tolerogenic properties, that is, reducing the infiltration of macrophages into the CNS and inhibiting T cell proliferation in rats with EAE [141]. In MS patients, estrogen upregulates IDO expression on DCs and inhibits both Th1 and Th2 cytokines secretion [142]. Estrogen exerts its immune modulation role through its receptors α and β on DCs [143]. Although estrogen can relieve the symptoms of MS and reduce the incidence of relapses, it is not commonly used in clinic partly because of its side effects.

6.2. Vitamin D. The prevalence of MS increases as the latitude increases suggesting that the deficiency of sunshine increases the risk of MS [144]. It has been clearly established that vitamin D deficiency is a potential risk factor for MS [145], since the levels of vitamin D are lower in MS patients than in healthy subjects. Moreover, levels of vitamin D in MS patients suffering from relapse were lower than those during the remission stage [146]. Vitamin D plays an immunomodulatory role by its interaction with the vitamin D receptor (VDR), which is expressed on lymphocytes. 1, 25-dihydroxy vitamin D3 (1,25(OH)2D3) is the active form of vitamin D in vivo. The immunomodulatory function of vitamin D is carried out through several pathways [147] (Figure 4). 1,25(OH)2D3 ex vivo inhibits proliferation of MBP-specific T cells and increases the number of Tregs from MS patients [146]. Despite the effect on T cells, vitamin D also acts on DCs because of its immunomodulatory ability (Table 3). In vitro, 1,25(OH)2D3 can partially block the GM-CSF and IL-4-driven differentiation of monocytes into DCs [148]. When DCs, which differentiate from human monocytes in the presence of GM-CSF and IL-4 in vitro, were treated with 1,25(OH)2D3, their capacity to mature into APCs was inhibited [148]. Likewise, when monocyte-derived DCs from RRMS patients were treated with 1,25(OH)2D3 the DCs exhibited an immature phenotype and the secretion of IL-12p40 was inhibited while the secretion of CCL2 increased [149]. The immunomodulatory role of vitamin D is partly via its ability to inhibit the differentiation and maturation of DCs and to generate tolerogenic DCs [150]. Tolerogenic DCs induced by 1,25(OH)2D3 resulted in stable antigen-specific hyporesponsiveness in myelin-reactive T cells from RRMS patients when stimulated with myelin peptide [150]. Vitamin D-induced tolerogenic DCs showed a significant increase in STAT3 and IDO expression and adoptive transfer of tolerogenic DCs significantly reduced the severity of EAE [151]. All these studies demonstrated the vitamin D-induced tolerogenic DCs have potential immunotherapy value. In recent years, the use of vitamin D3 supplementation to prevent MS or to slow disease progression is under extensive investigation. Vitamin D3 supplementation appeared beneficial to MS patients to some extent. Burton et al. found that the immunological parameters of MS patients taking vitamin D3 supplements are altered [152]. MS patients treated with vitamin D3 have fewer relapse events and more persistent reduction in T-cell proliferation compared to controls [152]. Another study indicated that there were no significant changes in clinical or radiological parameters of MS patients following short-term treatment with vitamin D3 supplementation, but the levels of cell proliferation were decreased [153]. It is noteworthy that the side effects of vitamin D3 should be taken into consideration if it is used as the treatment of MS.

6.3. Cytokines. Cytokines have been evidenced to participate in the pathogenesis of MS and can be divided into two types according to their function: proinflammatory and anti-inflammatory cytokines. The former promotes the process of demyelination and axonal damage, aggravating the severity of MS, while the latter promotes the inflammation subsided and disease recovery in MS. DCs are able to secrete both types of cytokines depending on the different subtypes and maturation stages. Herein we summarize the cytokines that are secreted by DCs and that may have potentials for MS treatment (Table 4).

6.3.1. Interleukin-10 (IL-10). IL-10 is primarily produced by monocytes, macrophages, and different T cell subsets with the capacity to inhibit immune responses and induce immune tolerance. IL-10 can inhibit Th1 cells via multiple mechanisms. In addition, IL-10 can induce type 1 regulatory T cells (Tr1), which are essential in peripheral immune tolerance [154]. The main producers of IL-10 are Th2 cells, Tregs, and some types of DCs [155].
IL-10 exerts a "beneficial" role in MS by suppressing the autoimmune response through inhibiting self-antigen-specific T cells and inducing Tregs. IL-10 also could affect the function of DCs in MS. *In vitro*, DCs (monocyte-derived from MS patients) treated with IL-10 induced the production of IL-4 and IL-10 by autologous lymphocytes, while cDCs derived from MS and exposed to IL-10 became resistant to maturation induced by LPS [156]. The studies to date indicate that IL-10 is an important molecule that interferes with the maturation of DCs and induces tolerogenic DCs. Similarly,
IL-10-treated DCs exhibited transient maturation, which expressed low level of IL-12 and failed to stimulate T cell proliferation both in vivo and in vitro. Interaction with IL-10-treated DCs rendered antigen-specific T cells unresponsive to subsequent challenges and adoptive transfer IL-10-treated DCs reduced the severity of EAE [157]. Recently, treatment with IL-10 gene-transfected mature DCs was found to be effective in suppressing EAE [158]. Gene therapy has not been applied in MS patients due to several reasons, yet a newly identified subset of DCs, so called DC-10, provides us with new perspectives. Unlike immature DCs and IL-10-treated DCs, DC-10 is a tolerogenic DC that has a stable mature phenotype due to its high expression of HLA-II and costimulatory molecules. DC-10 secretes high level of IL-10, together with the tolerogenic molecule HLA-G and the immunoglobulin-like transcript 4 inducer type I Tregs, which play an important role in peripheral tolerance [159]. DC-10 can differentiate from peripheral blood monocytes in the presence of GM-CSF, IL-4, and IL-10 [160]. Inducing the generation of DC-10 or IL-10-treated DCs in vitro then injecting them back into MS patients may be a potential therapeutic method in MS. However, it is necessary to conduct animal experiments and clinical trials to determine the safety and efficacy of this therapeutic alternative.

6.3.2. TGF-β. Transforming growth factor- (TGF-) β is another anti-inflammatory cytokine. Nasal administration of low-dose TGF-β1 inhibited the development and relapse of protracted-relapsing EAE (PR-EAE) in DA rats [161]. Further studies showed that TGF-β1-induced suppression of PR-EAE is associated with apoptosis of CD4+ T cells induced by DC-derived nitric oxide [162]. TGF-β1-treated DCs exhibited the characteristics of immature or tolerogenic DCs, which had a lower capacity to stimulate T cells. Additionally, TGF-β1-treated DCs are potential therapeutic in Lewis rat with EAE [163]. TGF-β is necessary for the conversion of Th0 cells into Th17 cells. Integrin αvβ8 expression on DCs can activate TGF-β and is critical in the differentiation of Th17 cells [164]. More importantly, integrin αvβ8 on DCs is necessary for the induction of EAE, while mice lack of integrin αvβ8 showed nearly complete protection from EAE [165]. When αv integrin expression on DCs was inhibited following drug treatment, TGF-β activation was blocked and Th17 generation was suppressed, which conferred protection from EAE in mice [165]. Therefore, TGF-β may have a potential therapeutic role in MS by two ways. Firstly, DCs treated with TGF-β can induce tolerogenic DCs, which could be used for cell therapy in MS. Secondly, drugs can be designed to target αv integrin on DCs to inhibit Th17 differentiation, and thus it achieves therapeutic purposes in MS.

6.3.3. IL-12/IL-23. Besides, both IL-12 and IL-23 are proinflammatory cytokines secreted by APCs and can induce encephalitogenic T cells. IL-12 induces naïve T cells differentiation into Th1 cells, while IL-23 is associated with the differentiation of Th17 cells [166]. IL-12 and IL-23 have the common subunit IL-12/23p40. Anti-IL-12/23p40 antibody significantly ameliorated EAE in rodents [150, 131] and non-human primates [132, 133]. Unfortunately, clinical trials in phases I and II using antibody against IL-12/23p40 (ustekinumab) in MS patients received conflicting results [134, 135]. ABT-874 is another monoclonal anti-IL-12/23 antibody, which exhibits similar safety as ustekinumab in patients with lack of efficacy for disease [136].

6.3.4. IL-17, IL-21, and IL-22. The IL-17 family includes six family members, namely, IL-17 A-F. In all of these family members, IL-17A is more critical in EAE than the others. The development of EAE IL-17A knock-out mice was significantly suppressed [167]. Neutralizing antibodies against IL-17A also ameliorated EAE symptoms [168]. Although further studies showed that IL-17A and IL-17F may only marginally contribute to the development of EAE [169], most researchers believed that IL-17A is dispensable for EAE induction. IL-17 gene polymorphism was found in all patients with each subtype of MS [170]. These findings imply that IL-17 may exert important roles in MS. Monoclonal antibodies against IL-17A have passed through phase II clinical trials. Th17 can secrete IL-21 and IL-22 as well. Mice deficient in IL-22, IL-21, and IL-21 receptors were all susceptible to EAE induction [171–173]. In IL-21 and IL-21 receptor knock-out mice, Th17 development and recruitment to CNS were normal [173]. These findings indicate that IL-21 and IL-22 are not effector cytokines in EAE. During the induction and peak phases of EAE, however, the levels of IL-22 were elevated [174]. More importantly, IL-22 was elevated in the serum of patients with MS [175].

6.3.5. IL-1β. IL-1β is an important pathogenic cytokine in EAE. IL-1β receptor knock-out mice have a significant reduction in disease severity during EAE [176]. IL-1β receptor knock-out mice show significant decrease in VCAM-1 expression and diminished leukocytes infiltration in the spinal cord in animals challenged with EAE [177]. Th17 differentiation was also affected [177]. In brain lesions of patients with MS, high levels of IL-1β were found [178].

6.3.6. GM-CSF. GM-CSF is IL-23 driven cytokines in EAE and is required for Th17 to become encephalitogenic cells [179]. Moreover, GM-CSF would enhance IL-23 secretion by APCs [179]. Autoreactive T helper cells specifically lacking GM-CSF failed to induce EAE despite expression of IL-17A or IFN-γ, whereas GM-CSF secretion by IFNγ−/− IL-17A−/− helper T cells was sufficient to induce EAE [180]. During the disease effector phase, GM-CSF sustained neuroinflammation via myeloid cells that infiltrated the CNS [180]. Langerin (+) CD103 (+) DCs play a key role in EAE, which activate encephalitogenic T cells in the periphery prior to other DCs. Their accumulation in the skin and peripheral lymph nodes is dependent on GM-CSF [181]. GM-CSF is also critical in either initiation or plateau stages of EAE. Phase II clinical trials on monoclonal antibodies against GM-CSF have been finished.

6.3.7. TNF-α. There are two kinds of TNF-α, membrane bound TNF-α (mTNF-α) and soluble form TNF-α. TNFR1 is widely expressed and may bind two kinds of TNF, while TNFR2 is expressed on lymphocytes and binds to soluble membrane bound TNF-α [182]. TNF-α is a proinflammatory
cytokine, so mice treated with antibody against TNF-α were found resistant to EAE [183]. Mice deficient in TNFR1 or TNFR2 were resistant to EAE, whereas mice deficient in TNFR2 exhibited severe EAE symptoms [184, 185]. These studies suggested that mTNF signaling with TNFR2 has a protection role [186]. This protection role could explain why plenty of patients treated with anti-TNF-α agent in clinical trials result in disease aggravation [187].

6.3.8. IL-6. IL-6 is a proinflammatory cytokine; together with TGF-β, IL-6 promotes Th17 differentiation. IL-6 knockout mice are completely resistant to EAE induction [188]. IL-6 receptor blockade prevents EAE induction through inhibiting Th17 differentiation [189]. Recently researchers have found that the key cells that are required to produce IL-6 to drive EAE are DCs. At the initial stage of EAE, DCs derived IL-6 is critical for T cell activation and EAE induction [190]. In MS patients, IL-6 was found in the brain. This suggests that IL-6 participates in the pathogenesis of MS [191]. Tocilizumab is a blocking antibody against the IL-6 receptor. In clinical trials, beneficial effects have been shown on rheumatoid arthritis. There has been no clinical trial on this drug as yet, whereas a recent case report showed that treatment with tocilizumab has positive effects on patients with neuromyelitis optica [192]. Thus, tocilizumab would be an effective therapy for CNS demyelinating disorders.

7. Will DCs Be a Therapeutic Tool for MS in Future?

As previously mentioned, DCs are important in the pathogenesis of MS and current options for MS directly or indirectly affect DCs function. Recently, cell therapy has become hot spot in cancer, transplant, and autoimmune diseases. As its double role in MS, DCs would be an ideal tool for cell therapy. At present, it is hard to achieve in patients with MS, while in basic research, researchers used kinds of methods modifying DCs in vitro and then adoptive transfer of the modified DCs to EAE model. Early in 2002 Menges et al. showed that repetitive injections of TNFα-matured DCs plus peptide protected mice from EAE induction [193]. Hirata et al. used genetic skills modified DCs, making DC presenting MOG peptide in the context of MHC class II molecules and simultaneously expressing TRAIL or PD-L1. Mice treated with such modified DCs had ameliorated MOG peptide-induced EAE scores; the T cell response to MOG and cell infiltration in spinal cord were also reduced [194]. Treatment of DCs with chloroquine (CQ) induced tolerogenic DCs, and adoptive transfer CQ-DCs to EAE mice would reduce the clinical manifestation of the disease [195]. Moreover, Zhou et al. recently find either intravenous transfer of LPS-treated DCs or apoptotic cell-treated DCs blocking EAE [196, 197].

pDC is another subset of DCs, the pathogenesis roles of which on EAE are interesting. At first, researchers found that CNS pDCs suppressed CNS mDC-driven production of IL-17, IFN-γ, and IL-10 in an IDO-independent manner. They concluded that pDCs play a critical regulatory role in negatively regulating pathogenic CNS CD4(+) T cell responses [56]. Then, Isaksson et al. used anti-PDCA1 antibodies to deplete pDCs at different stages of EAE and found that pDCs had different roles in different stages of EAE. When pDCs were depleted prior to MOG induction, pDC-depleted mice developed less severe EAE, which implied that pDCs have a promoting role in the initiation phase of EAE [198]. When pDCs were deleted a week after the immunization, pDC-depleted mice developed more severe symptoms, demonstrating a protecting role of pDCs in EAE [198]. After EAE is induced, pDCs are recruited to lymph nodes where MHC-II-dependent myelin-Ag-specific contacts with CD4+ T cells are established. These interactions may promote the selective expansion of natural Tregs to inhibit the autoimmune T cell response [57]. Taken together, pDCs’ protective roles in EAE enlighten us that pDCs would be one of effective therapeutic options for MS. For instance, we can increase the amount of pDCs in CNS to suppress the pathogenic CNS CD4+ T cell responses. We can also transfer myelin-Ag-loaded pDCs to stimulate Treg induction by pDCs, which may eventually benefit MS patients [57].

8. Conclusion

In summary, we summarized the role of DCs in the pathogenesis of MS and current therapeutic options for MS affected the subset and function of DCs. The development of novel therapy to target DCs is therefore essential. Drugs and cytokines that have potential therapeutic effects on MS may be an alternative option. Targeted therapies against detrimental DCs in MS would be promising in the future.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Zhong-Xiang Xie and Hong-Liang Zhang contributed equally to the work.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (nos. 81301021, 81241147, 81271294, 81271293, and 81471216), the Young Scholars Program of Norman Bethune Health Science Center of Jilin University (no. 2013205035), the Jilin Province Department of Public Health research project (no. 20111010), the Young Scholars Program of Jilin Provincial Science and Technology Development of China (no. 20130522025), the Young Scholars Program of Jilin Provincial Science and Technology Development of China (no. 20130522025), the Young Scholars Program of Jilin University (no. 20130522025), and the Young Scholars Program of the First Hospital of Jilin University (JDYY42013003 and JDYY42013005).
in cortical multiple sclerosis lesions,” *Annals of Neurology*, vol. 50, no. 3, pp. 389–400, 2001.

[2] M. Merad, P. Sathe, J. Helft, J. Miller, and A. Mortha, “The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting,” *Annual Review of Immunology*, vol. 31, pp. 563–604, 2013.

[3] D. Vremec, J. Pooley, H. Hochrein, L. Wu, and K. Shortman, “CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen,” *Journal of Immunology*, vol. 164, no. 6, pp. 2978–2986, 2000.

[4] K. Shortman and Y. J. Liu, “Mouse and human dendritic cell subtypes,” *Nature Reviews Immunology*, vol. 2, no. 3, pp. 151–161, 2002.

[5] R. Maldonado-Lopez, T. de Smedt, P. Michelet et al., “CD8alpha+ and CD8alpha− subclasses of dendritic cells direct the development of distinct T helper cells in vivo,” *The Journal of Experimental Medicine*, vol. 189, no. 3, pp. 587–592, 1999.

[6] B. Pulendran, J. L. Smith, G. Caspary et al., “Distinct dendritic cell subsets differentially regulate the class of immune response in vivo,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 96, no. 3, pp. 1036–1041, 1999.

[7] D. Piccoli, S. Tavarini, E. Borgognini et al., “Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets,” *Blood*, vol. 109, no. 12, pp. 5371–5379, 2007.

[8] L. Ziegler-Heitbrock, “The CD14+ CD16+ blood monocytes: their role in infection and inflammation,” *Journal of Leukocyte Biology*, vol. 81, no. 3, pp. 584–592, 2007.

[9] D. Mittag, A. L. Proietto, T. Loudovaris et al., “Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status,” *Journal of Immunology*, vol. 186, no. 11, pp. 6207–6217, 2011.

[10] S. L. Jongbloed, A. J. Kassianos, K. J. McDonald et al., “Human CD14+CD16+ blood monocytes: implications for dendritic cell-based anti-cancer immunotherapy,” *Frontiers in Immunology*, vol. 3, article 123, 2012.

[11] G. Schreibelt, J. Tel, K. H. E. W. J. Sliepen et al., “Distribution and phenotype of dendritic cell subsets in human peripheral blood,” *European Journal of Immunology*, vol. 42, no. 6, pp. 1512–1522, 2012.

[12] A. J. Kassianos, M. Y. Hardy, X. Ju et al., “Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli,” *European Journal of Immunology*, vol. 42, no. 6, pp. 1512–1522, 2012.

[13] A. Dzinec, A. Fuchs, P. Schmidt et al., “BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood,” *The Journal of Immunology*, vol. 165, no. 11, pp. 6037–6046, 2000.

[14] F. P. Siegal, N. Kadowaki, M. Shodell et al., “The nature of the principal type 1 interferon-producing cells in human blood,” *Science*, vol. 284, no. 5421, pp. 1835–1837, 1999.

[15] N. Kadowaki, S. Antonenko, J. Y.-N. Lau, and Y.-J. Liu, “Natural interferon α/β-producing cells link innate and adaptive immunity,” *The Journal of Experimental Medicine*, vol. 192, no. 2, pp. 219–225, 2000.

[16] G. Jego, A. K. Palucka, J. P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau, “Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6,” *Immunity*, vol. 19, no. 2, pp. 225–234, 2003.

[17] N. Schwab, A. L. Zozulya, B. C. Kieseier, K. V. Toyka, and H. Wiendl, “An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis,” *The Journal of Immunology*, vol. 184, no. 9, pp. 5368–5374, 2010.

[18] M. Mittelbrunn, G. M. Del Hoyo, L.-B. Maria et al., “Imaging of plasmacytoid dendritic cell interactions with T cells,” *Blood*, vol. 113, no. 1, pp. 75–84, 2009.

[19] H. Ueno, N. Schmitt, E. Klechevsky et al., “Harnessing human dendritic cell subsets for medicine,” *Immunological Reviews*, vol. 234, no. 1, pp. 199–212, 2010.

[20] W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar, “The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation,” *The Journal of Immunology*, vol. 181, no. 8, pp. 5396–5404, 2008.

[21] T. Ito, M. Yang, Y.-H. Wang et al., “Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand,” *The Journal of Experimental Medicine*, vol. 204, no. 1, pp. 105–115, 2007.

[22] M. Isaksson, B. A. Lundgren, K. M. Ahlgren, O. Kämpe, and A. Lobell, “Conditional DC depletion does not affect priming of encephalitogenic Th cells in EAE,” *European Journal of Immunology*, vol. 42, no. 10, pp. 2555–2563, 2012.

[23] M. B. Lutz, “Therapeutic potential of semi-mature dendritic cells for tolerance induction,” *Frontiers in Immunology*, vol. 3, pp. 1–12, 2013.

[24] G. Locatello, G. Amadio, D. Tomasini, C. Tresoldi, F. Ciceri, and S. Gregori, “HLA-G expression on blasts and tolerogenic cells in patients affected by acute myeloid leukemia,” *Journal of Immunology Research*, vol. 2014, no. 10, Article ID 636292, 2014.

[25] A. E. Morelli and A. W. Thomson, “Tolerogenic dendritic cells and the quest for transplant tolerance,” *Nature Reviews Immunology*, vol. 7, no. 8, pp. 610–621, 2007.

[26] C. A. Colton, “Immune heterogeneity in neuroinflammation: dendritic cells in the brain,” *Journal of Neuroimmunology*, vol. 8, no. 1, pp. 145–162, 2013.

[27] G. Brandacher, R. Margreiter, and D. Fuchs, “Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation,” *Current Opinion in Organ Transplantation*, vol. 13, no. 1, pp. 10–15, 2008.

[28] R. A. Maldonado and U. H. von Andrian, “How tolerogenic dendritic cells induce regulatory T cells,” *Advances in Immunology*, vol. 108, pp. 111–165, 2010.

[29] H. Jönuleit, E. Schmitt, G. Schuler, J. Knop, and A. H. Enk, “Induction of interleukin 10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells,” *The Journal of Experimental Medicine*, vol. 192, no. 9, pp. 1213–1222, 2000.

[30] C. M. U. Hilkens, J. D. Isaacs, and A. W. Thomson, “Development of dendritic cell-based immunotherapy for autoimmunity,” *International Reviews of Immunology*, vol. 29, no. 2, pp. 156–183, 2010.

[31] P. G. McMenamin, “Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations,” *Journal of Comparative Neurology*, vol. 405, no. 4, pp. 553–562, 1999.

[32] J.-M. Serot, M. C. Béné, B. Foliguet, and G. C. Faure, “Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium,” *Journal of Neuroimmunology*, vol. 105, no. 2, pp. 115–119, 2000.
Mediators of Inflammation

[33] M. Pashenkov, Y.-M. Huang, V. Kostulas, M. Haglund, M. Söderström, and H. Link, “Two subsets of dendritic cells are present in human cerebrospinal fluid,” Brain, vol. 124, no. 3, pp. 480–492, 2001.

[34] C. Prodinger, J. Bunse, M. Krüger et al., “CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system,” Acta Neuropathologica, vol. 121, no. 4, pp. 445–458, 2011.

[35] L. Santambrogio, S. L. Belyanskaya, F. R. Fischer et al., “Flt3L expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis,” Autoimmunity, vol. 43, no. 7, pp. 504–513, 2010.

[36] D. Ganguly, S. Haak, V. Sisirak, and B. Reizis, “The role of dendritic cells in autoimmunity,” Nature Reviews Immunology, vol. 13, no. 8, pp. 566–577, 2013.

[37] S. S. Diebold, “Determination of T-cell fate by dendritic cells,” Immunology and Cell Biology, vol. 86, no. 5, pp. 389–397, 2008.

[38] E. M. Frohm, M. K. Racke, and C. S. Raine, “Medical progress: multiple sclerosis—the plaque and its pathogenesis,” The New England Journal of Medicine, vol. 354, no. 9, pp. 942–955, 2006.

[39] A. Slavin, L. Kelly-Modis, M. Labadia, K. Ryan, and M. L. Brown, “Pathogenic mechanisms and experimental models of multiple sclerosis,” Autoimmunity, vol. 43, no. 7, pp. 504–513, 2010.

[40] M. Greter, F. L. Heppner, M. P. Lemos et al., “Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis,” Nature Medicine, vol. 11, no. 3, pp. 328–334, 2005.

[41] E. J. McMahon, S. L. Bailey, C. V. Castenada, H. Waldner, and S. D. Miller, “Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis,” Nature Medicine, vol. 11, no. 3, pp. 335–339, 2005.

[42] N. Anandasabapathy, G. D. Victora, M. Meredith et al., “Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain,” The Journal of Experimental Medicine, vol. 208, no. 8, pp. 1695–1705, 2011.

[43] D. O. Willenborg and M. A. Staykova, “Cytokines in the pathogenesis and therapy of autoimmune encephalomyelitis and multiple sclerosis,” Advances in Experimental Medicine and Biology, vol. 520, pp. 96–119, 2003.

[44] J. F. Curtin, G. D. King, C. Barcia et al., “Fins-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain,” Journal of Immunology, vol. 176, no. 6, pp. 3566–3577, 2006.

[45] N. Anandasabapathy, G. D. Victora, M. Meredith et al., “Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain,” The Journal of Experimental Medicine, vol. 208, no. 8, pp. 1695–1705, 2011.

[46] M. Pashenkov, N. Teleshova, M. Kouwenhoven et al., “Elevated chemokine production by dendritic cells upon CD46 activation contributes of CD4+ regulatory T cells,” Immunity, vol. 37, no. 2, pp. 264–275, 2012.

[47] S. Takizawa, T. Kaneyama, S. Tsugane et al., “Role of the Programmed Death-1 (PD-1) pathway in regulation of Th17 cell-mediated autoimmune responses,” Journal of Immunology, vol. 174, no. 1-2, pp. 78–85, 2014.

[48] M. Irla, N. Küpper, T. Suter et al., “MHC class II-restricted antigen presentation by plasmacytoid dendritic cells inhibits T cell-mediated autoimmunity,” Journal of Experimental Medicine, vol. 207, no. 9, pp. 1891–1905, 2010.

[49] Y.-M. Huang, B.-G. Xiao, V. Özenç et al., “Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines,” Journal of Neuroimmunology, vol. 99, no. 1, pp. 82–90, 1999.

[50] M. Pashenkov, N. Teleshova, M. Kouwenhoven et al., “Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis,” Clinical & Experimental Immunology, vol. 127, no. 3, pp. 519–526, 2002.

[51] G. F. Wu and T. M. Lauffer, “The role of dendritic cells in multiple sclerosis,” Current Neurology and Neuroscience Reports, vol. 7, no. 3, pp. 245–252, 2007.

[52] A. Karni, M. Abraham, A. Monsonego et al., “Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response,” Journal of Immunology, vol. 177, no. 6, pp. 4196–4202, 2006.

[53] C. López, M. Comabella, H. Al-zayat, M. Tintoré, and X. Montalban, “Altered maturation of circulating dendritic cells in primary progressive MS patients,” Journal of Neuroimmunology, vol. 175, no. 1-2, pp. 183–191, 2006.

[54] A. Vaknin-Dembinsky, G. Murugaiyan, D. A. Hafer, A. L. Astier, and H. L. Weiner, “Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation...
in patients with multiple sclerosis,” *Journal of Neuroimmunology*, vol. 195, no. 1-2, pp. 140–145, 2008.

[64] L. A. Boven, L. Montagne, H. S. L. M. Nottet, and C. J. A. de Groot, “Macrophage inflammatory protein-lalphal (MIP-lalphal), MIP-1b, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions,” *Clinical and Experimental Immunology*, vol. 122, no. 2, pp. 257–263, 2000.

[65] R. Lande, V. Gafa, B. Serafini et al., “Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-β,” *Journal of Neuropathology and Experimental Neurology*, vol. 67, no. 5, pp. 388–401, 2008.

[66] A. L. F. Longhini, F. von Glehn, C. O. Brandão et al., “Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse,” *Journal of Neuroinflammation*, vol. 8, no. 1, article 2, 2011.

[67] M. Stasiolek, A. Bayas, N. Kruse et al., “Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis,” *Brain*, vol. 129, no. 5, pp. 1293–1305, 2006.

[68] L. L. Aung, P. Fitzgerald-Bocarsly, S. Dhib-Jalbut, and K. J. Navarro, C. Aristimuño, S. Sánchez-Ramón et al., “Circulating dendritic cells are increased in cerebrospinal fluid of untreated patients during multiple sclerosis relapse,” *Journal of Neuroinflammation*, vol. 8, no. 1, article 2, 2011.

[69] M. Stasiolek, A. Bayas, N. Kruse et al., “Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis,” *Brain*, vol. 129, no. 5, pp. 1293–1305, 2006.

[70] L. L. Aung, P. Fitzgerald-Bocarsly, S. Dhib-Jalbut, and K. Balashov, “Plasmacytoid dendritic cells in multiple sclerosis: chemokine and chemokine receptor modulation by interferon-beta,” *Journal of Neuroimmunology*, vol. 226, no. 1-2, pp. 158–164, 2010.

[71] J. Navarro, C. Aristimuño, S. Sánchez-Ramón et al., “Circulating dendritic cells subsets and regulatory T-cells at multiple sclerosis relapse: differential short-term changes on corticosteroids therapy,” *Journal of Neuroimmunology*, vol. 176, no. 1-2, pp. 153–161, 2006.

[72] M.-S. Krystyna, T. Jacek, R. Sebastian et al., “Changes in circulating dendritic cells and B-cells in patients with multiple sclerosis relapse during corticosteroid therapy,” *Journal of Neuroimmunology*, vol. 207, no. 1-2, pp. 107–110, 2009.

[73] Y.-M. Huang, N. Stoyanova, Y.-P. Jin et al., “Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-β and IL-10,” *Clinical and Experimental Immunology*, vol. 124, no. 2, pp. 306–314, 2001.

[74] H. C. Heystek, B. den Drijver, M. L. Kapsenberg, R. A. W. van Lier, and E. C. de Jong, “Type I IFNs differentially modulate IL-12p70 production by human dendritic cells depending on the maturation status of the cells and counteract IFN-γ-mediated signaling,” *Clinical Immunology*, vol. 107, no. 3, pp. 170–177, 2003.

[75] X. Zhang, J. Jin, Y. Tang, D. Speer, D. Sujkowska, and S. Markovic-Plese, “IFN-β1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation,” *Journal of Immunology*, vol. 182, no. 6, pp. 3928–3936, 2009.

[76] C. M. Sweeney, R. Loneragan, S. A. Basdeo et al., “IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells,” *Brain, Behavior, and Immunology*, vol. 25, no. 6, pp. 1170–1181, 2011.

[77] E. Wiesemann, D. Sönmez, F. Heidenreich, and A. Windhagen, “Interferon-β increases the stimulatory capacity of monocytoid dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells,” *Journal of Neuroimmunology*, vol. 123, no. 1-2, pp. 160–169, 2002.

[78] B. Schreiner, M. Mitsdoerffer, B. C. Kieseier et al., “Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis,” *Journal of Neuroimmunology*, vol. 155, no. 1-2, pp. 172–182, 2004.

[79] D. S. Kim, K. S. Cho, Y. H. Lee, N. H. Cho, Y. T. Oh, and S. J. Hong, “High-grade hydronephrosis predicts poor outcomes after radical cystectomy in patients with bladder cancer,” *Journal of Korean Medical Science*, vol. 25, no. 3, pp. 369–373, 2010.

[80] M. Chen, G. Chen, S. Deng, X. Liu, G. J. Hutton, and J. Hong, “IFN-β induces the proliferation of CD4+CD25+ FoxP3+ regulatory T cells through upregulation of GITRL on dendritic cells in the treatment of multiple sclerosis,” *Journal of Neuroimmunology*, vol. 242, no. 1-2, pp. 39–46, 2012.

[81] L. L. Aung, A. Brooks, S. A. Greenberg, M. L. Rosenberg, S. Dhíb-Jalbut, and K. E. Balashov, “Multiple sclerosis-linked and interferon-beta-regulated gene expression in plasmacytoid dendritic cells,” *Journal of Neuroimmunology*, vol. 250, no. 1-2, pp. 99–105, 2012.

[82] S. Bakshi, V. Chalifa-Caspi, I. Plaschkes, I. Perevozkin, M. Gurevich, and R. Schwartz, “Gene expression analysis reveals functional pathways of glatiramer acetate activation,” *Expert Opinion on Therapeutic Targets*, vol. 17, no. 4, pp. 351–362, 2013.

[83] Y. Hussien, A. Sanna, M. Söderström, H. Link, and Y.-M. Huang, “Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis,” *Journal of Neuroimmunology*, vol. 121, no. 1-2, pp. 102–110, 2001.

[84] P. L. Vieira, H. C. Heystek, J. Wormmeester, E. A. Wierenga, and M. L. Kapsenberg, “Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells,” *Journal of Immunology*, vol. 170, no. 9, pp. 4483–4488, 2003.

[85] S. Begum-Haque, M. Christy, Y. Wang et al., “Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OIPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis,” *Journal of Neuroimmunology*, vol. 254, no. 1-2, pp. 117–124, 2013.

[86] M. Ruggieri, C. Pica, A. Lia et al., “Combination treatment of Glatiramer Acetate and Minocycline affects phenotype expression of blood monocyte-derived dendritic cells in Multiple Sclerosis patients,” *Journal of Neuroimmunology*, vol. 197, no. 2, pp. 140–146, 2008.

[87] F. Sellebjerg, D. Hesse, S. Limborg et al., “Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis,” *Multiple Sclerosis*, vol. 19, no. 2, pp. 179–187, 2013.

[88] K. L. Sand, E. Knudsen, J. Rolin, Y. Al-Falahi, and A. A. Maghazachi, “Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate,” *Cellular and Molecular Life Sciences*, vol. 66, no. 8, pp. 1446–1456, 2009.

[89] M. del Pilar Martin, P. D. Cravens, R. Winger et al., “Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab,” *Archives of Neurology*, vol. 65, no. 12, pp. 1596–1603, 2008.

[90] C. de Andrés, R. Tejeiro, B. Alonso et al., “Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis,” *PloS ONE*, vol. 7, no. 4, Article ID e34103, 2012.

[91] V. Brinkmann, A. Billich, T. Baumruker et al., “Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis,” *Nature Reviews Drug Discovery*, vol. 9, no. 11, pp. 883–897, 2010.
[90] L. Kappos, E.-W. Radue, P. O’Connor et al., “A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis,” The New England Journal of Medicine, vol. 362, no. 5, pp. 387–401, 2010.

[91] L. Tar and L. Vécsei, “Fingolimod therapy in multiple sclerosis—the issue of the pathomechanism,” Ideggyógyászati Szemle, vol. 65, no. 3-4, pp. 83–100, 2012.

[92] H. Müller, S. Hofer, N. Kaneider et al., “The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells,” European Journal of Immunology, vol. 35, no. 2, pp. 533–545, 2005.

[93] Y. Y. Lan, A. De Creus, B. L. Colvin et al., “The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking In Vivo,” American Journal of Transplantation, vol. 5, no. 11, pp. 2649–2659, 2005.

[94] B. A. Durafort, C. Lambert, T. A. Johnson, M. Blain, A. Bar-Or, and J. P. Antel. “Differential responses of human microglia and blood-derived myeloid cells to FTY720,” Journal of Neuroimmunology, vol. 230, no. 1-2, pp. 10–16, 2011.

[95] T. Vollmer, T. Stewart, and N. Baxter, “Mitoxantrone and cytotoxic drugs’ mechanisms of action,” Neurology, vol. 74, supplement 1, pp. S41–S46, 2010.

[96] O. Neuhaus, H. Wiendl, B. C. Kieseier et al., “Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro,” Journal of Neuroimmunology, vol. 168, no. 1-2, pp. 128–137, 2005.

[97] J. M. Li, Y. Yang, P. Zhu, F. Zheng, F. L. Gong, and Y. W. Mei, “Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells,” Immunopharmacology and Immunotoxicology, vol. 34, no. 1, pp. 36–41, 2012.

[98] A. Aldinucci, T. Biagioli, C. Manuelli, A. M. Repice, L. Masesci, and C. Ballerini, “Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: A novel mechanism of AZA6-MP” Journal of Neuroimmunology, vol. 218, no. 1-2, pp. 28–35, 2010.

[99] A. Haghikia and R. Gold, “Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS,” Nature Reviews Neurology, vol. 10, no. 4, pp. 183–184, 2014.

[100] A. Sartori, D. Carle, and M. S. Freedman, “Teriflunomide: a novel oral agent for multiple sclerosis,” Annals of Pharmacotherapy, vol. 47, no. 12, pp. 1697–1702, 2013.

[101] R. H. Scannevin, S. Chollate, M.-Y. Jung et al., “Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 341, no. 1, pp. 274–284, 2012.

[102] H. Peng, M. Guerou-de-Arellano, V. B. Mehta et al., “Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor κB (NF-κB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling,” The Journal of Biological Chemistry, vol. 287, no. 33, pp. 28078–28086, 2012.

[103] K. Ghoreschi, J. Bruck, C. Kellerer et al., “Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells,” The Journal of Experimental Medicine, vol. 208, no. 11, pp. 2291–2303, 2011.

[104] W. Bruck and C. Wegner, “Insight into the mechanism of laquinimod action,” Journal of the Neurological Sciences, vol. 306, no. 1-2, pp. 173–179, 2011.

[105] V. Jolivel, F. Lussi, J. Masri et al., “Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis,” Brain, vol. 136, no. 4, pp. 1048–1066, 2013.

[106] G. Comi, D. Jeffery, L. Kappos et al., “Placebo-controlled trial of oral laquinimod for multiple sclerosis,” The New England Journal of Medicine, vol. 366, no. 11, pp. 1000–1009, 2012.

[107] M. Filippi, M. A. Rocca, E. Pagani et al., “Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 85, no. 8, pp. 851–858, 2014.

[108] T. L. Vollmer, P. S. Sorensen, K. Selmaj et al., “A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis,” Journal of Neurology, vol. 261, no. 4, pp. 773–783, 2014.

[109] R. Martin, “Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis,” Clinical Immunology, vol. 142, no. 1, pp. 9–14, 2012.

[110] R. Gold, G. Giovannoni, K. Selmaj et al., “Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 381, no. 9884, pp. 2167–2175, 2013.

[111] H. Wiendl and C. C. Gross, “Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis,” Nature Reviews Neurology, vol. 9, no. 7, pp. 394–404, 2013.

[112] K. Mnasria, C. Lagaraine, F. Velge-Roussel, R. Oueslati, Y. Lebranchu, and C. Baron, “Anti-CD25 antibodies affect cytokine synthesis pattern of human dendritic cells and decrease their ability to prime allogeneic CD4+ T cells,” Journal of Leukocyte Biology, vol. 84, no. 2, pp. 460–467, 2008.

[113] K. S. Schluns, “Window of opportunity for daclizumab,” Nature Medicine, vol. 17, no. 5, pp. 545–547, 2011.

[114] S. C. Wuest, J. H. Edwan, J. F. Martin et al., “A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy,” Nature Medicine, vol. 17, no. 5, pp. 604–609, 2011.

[115] L. Klotz, S. G. Meuth, and H. Wiendl, “Immune mechanisms of new therapeutic strategies in multiple sclerosis—a focus on alemtuzumab,” Clinical Immunology, vol. 142, no. 1, pp. 25–30, 2012.
[122] H.-P. Hartung, O. Aktas, and A. N. Boyko, “Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis,” Multiple Sclerosis Journal, 2014.

[123] R. A. Diaz, S. Doss, M. J. Burke, E. George, and A. I. Adler, “Alemtuzumab for relapsing-remitting multiple sclerosis,” The Lancet Neurology, vol. 13, no. 9, pp. 869–870, 2014.

[124] G. Ratzinger, J. L. Reagan, G. Keller, K. J. Busam, and J. W. Young, “Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation,” Blood, vol. 101, no. 4, pp. 1422–1429, 2003.

[125] A. G. S. Buggins, G. J. Mufti, J. Salisbury et al., “Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab,” Blood, vol. 100, no. 5, pp. 1715–1720, 2002.

[126] B. M. Kirsch, M. Haidinger, M. Zeyda et al., “Alemtuzumab (Campath-1H) induction therapy and dendritic cells: impact on peripheral dendritic cell repertoire in renal allograft recipients,” Transplant Immunology, vol. 16, no. 3–4, pp. 254–257, 2006.

[127] E. Havrdová, A. Belova, A. Goloborodko et al., “Positive proof of concept of AIN457, an antibody against interleukin-17A, in relapsing-remitting multiple sclerosis,” Multiple Sclerosis Journal, vol. 18, p. 513, 2012.

[128] A. Deiß, I. Brecht, A. Haarmann, and M. Buttmann, “Treating multiple sclerosis with monoclonal antibodies: a 2013 update,” Expert Review of Neurotherapeutics, vol. 13, no. 3, pp. 313–335, 2013.

[129] J. A. Hamilton, “ Colony-stimulating factors in inflammation and autoimmunity,” Nature Reviews Immunology, vol. 8, no. 7, pp. 533–544, 2008.

[130] M. Ichikawa, C. S. Koh, A. Inoue et al., “Anti-IL-12 antibody induces a potent suppression of experimental autoimmunity in marmosets using an anti-IL-12p40 monoclonal antibody,” The Journal of Immunology, vol. 169, no. 11, pp. 5654–5663, 2002.

[131] C. S. Constantinescu, M. Wysocka, B. Hilliard et al., “Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 161, no. 9, pp. 5097–5104, 1998.

[132] H. P. M. Brok, M. van Meurs, E. Blezer et al., “Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody,” The Journal of Immunology, vol. 169, no. 11, pp. 6554–6563, 2002.

[133] B. A. ‘t Hart, H. P. M. Brok, E. Remarque et al., “Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody,” The Journal of Immunology, vol. 175, no. 7, pp. 4761–4768, 2005.

[134] L. H. Kasper, D. Evertt, T. P. Leistet et al., “A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis,” Current Medical Research & Opinion, vol. 22, no. 9, pp. 1671–1678, 2006.

[135] B. M. Segal, C. S. Constantinescu, A. Raychaudhuri, L. Kim, R. Fidelus-Gort, and L. H. Kasper, “Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study,” The Lancet Neurology, vol. 7, no. 9, pp. 796–804, 2008.

[136] T. L. Vollmer, D. R. Wynn, S. M. Alam, and J. Valdes, “A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis,” Multiple Sclerosis, vol. 17, no. 2, pp. 181–191, 2011.

[137] W. J. Trooster, A. W. Teelken, J. Kampinga, J. G. Loof, P. Niewenhuis, and J. M. Minderhoud, “Suppression of acute experimental allergic encephalomyelitis by the synthetic sex hormone 17-alpha-ethyllestradiol: an immunological study in the Lewis rat,” International Archives of Allergy and Immunology, vol. 102, no. 2, pp. 133–140, 1993.

[138] L. Jansson, T. Olsson, and R. Holmdahl, “Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice,” Journal of Neuroimmunology, vol. 53, no. 2, pp. 203–207, 1994.

[139] H. Y. Liu, A. C. Buenafe, A. Matejuk et al., “Estrogen inhibition of EAE involves effects on dendritic cell function,” Journal of Neuroscience Research, vol. 70, no. 2, pp. 238–248, 2002.

[140] Q.-H. Zhang, Y.-Z. Hu, J. Cao, Y.-Q. Zhong, Y.-F. Zhao, and Q.-B. Mei, “Estrogen influences the differentiation, maturation and function of dendritic cells in rats with experimental autoimmune encephalomyelitis,” Acta Pharmacologica Sinica, vol. 25, no. 4, pp. 508–513, 2004.

[141] A. Pettersson, C. Ciumas, V. Chirsky, H. Link, Y.-M. Huang, and B.-G. Xiao, “Dendritic cells exposed to estrogen in vitro exhibit therapeutic effects in ongoing experimental allergic encephalomyelitis,” Journal of Neuroimmunology, vol. 156, no. 1-2, pp. 58–65, 2004.

[142] W.-H. Zhu, C.-Z. Lu, Y.-M. Huang, H. Link, and B.-G. Xiao, “A putative mechanism on remission of multiple sclerosis during pregnancy: estrogen-induced indoleamine 2,3-dioxygenase by dendritic cells,” Multiple Sclerosis, vol. 13, no. 1, pp. 33–40, 2007.

[143] S. Du, F. Sandoval, P. Trinh, E. Umeda, and R. Vouskhl, “Estrogen receptor-beta ligand treatment modulates dendritic cells in the target organ during autoimmune demyelinating disease,” European Journal of Immunology, vol. 41, no. 1, pp. 140–150, 2011.

[144] S. Simpson Jr., L. Blizzard, P. Otahal, I. van der Mei, and B. Taylor, “Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 82, no. 10, pp. 1132–1141, 2011.

[145] S. Hewer, R. Lucas, I. van der Mei, and B. V. Taylor, “Vitamin D and multiple sclerosis,” Journal of Clinical Neuroscience, vol. 20, no. 5, pp. 634–641, 2013.

[146] J. Correale, M. C. Yrraelit, and M. I. Gaiti, “Immunomodulatory effects of Vitamin D in multiple sclerosis,” Brain, vol. 132, no. 5, pp. 1146–1160, 2009.

[147] H.-L. Zhang and J. Wu, “Role of vitamin D in immune responses and autoimmune diseases, with emphasis on its role in multiple sclerosis,” Neuroscience Bulletin, vol. 26, no. 6, pp. 445–454, 2010.

[148] L. Piomonti, P. Monti, M. Sironi et al., “Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells,” Journal of Immunology, vol. 164, no. 9, pp. 4443–4451, 2000.

[149] H. Bartosik-Psujek, J. Tabarkiewicz, K. Pocinska, Z. Stelmasiak, and J. Rolinski, “Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis,” Multiple Sclerosis, vol. 16, no. 12, pp. 1513–1516, 2010.

[150] D. Raich-Regué, L. Grau-López, M. Naranjo-Gómez et al., “Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients,” European Journal of Immunology, vol. 42, no. 3, pp. 771–782, 2012.
[151] A. S. Farias, G. S. Spagnol, P. Bordeaux-Rego et al., "Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE," CNS Neuroscience and Therapeutics, vol. 19, no. 4, pp. 269–277, 2013.

[152] J. M. Burton, S. Kimball, R. Vieth et al., "A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis," Neurology, vol. 74, no. 23, pp. 1852–1859, 2010.

[153] G. Mosayebi, A. Ghazavi, K. Ghasami, Y. Jand, and P. Kohkhai, "Therapeutic effect of vitamin D3 in multiple sclerosis patients," Scandinavian Journal of Immunology, vol. 40, no. 6, pp. 627–639, 2011.

[154] R. Kushwah and J. Hu, "Role of dendritic cells in the induction of regulatory T cells," Cell and Bioscience, vol. 1, no. 1, article 20, 2011.

[155] D. M. Mosser and X. Zhang, "Interleukin-10: new perspectives on an old cytokine," Immunological Reviews, vol. 226, no. 1, pp. 205–218, 2008.

[156] S. B. Adikari, A. Pettersson, M. Soderstrom, Y.-M. Huang, and H. Link, "Interleukin-10-modulated immature dendritic cells control the proinflammatory environment in multiple sclerosis," Scandinavian Journal of Immunology, vol. 59, no. 6, pp. 600–606, 2004.

[157] G. Perona-Wright, S. M. Anderton, S. E. M. Howie, and D. Gray, "IL-10 permits transient activation of dendritic cells to tolerate T cells and protect from central nervous system autoimmune disease," International Immunology, vol. 19, no. 9, pp. 1123–1134, 2007.

[158] R. Matsuda, T. Kezuka, C. Nishiyama et al., "Interleukin-10 gene-transfected mature dendritic cells suppress murine experimental autoimmune optic neuritis," Investigative Ophthalmology and Visual Science, vol. 53, no. 11, pp. 7235–7245, 2012.

[159] S. Gregori, D. Tomasoni, V. Pacciani et al., "Differentiation of type 1 T regulatory cells (T1r) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway," Blood, vol. 116, no. 6, pp. 935–944, 2010.

[160] G. Amodio and S. Gregori, "Human tolerogenic DC-10: perspectives for clinical applications," Transplantation Research, vol. 1, no. 1, article 12, 2012.

[161] M. Ishikawa, Y. Jin, H. Guo, H. Link, and B.-G. Xiao, "Nasal administration of transforming growth factor-β1 induces dendritic cells and inhibits protracted-relapsing experimental allergic encephalomyelitis," Multiple Sclerosis, vol. 5, no. 3, pp. 184–191, 1999.

[162] Y.-X. Jin, L.-Y. Xu, H. Guo, M. Ishikawa, H. Link, and B.-G. Xiao, "TGF-β1 inhibits protracted-relapsing experimental autoimmune encephalomyelitis by activating dendritic cells," Journal of Autoimmunity, vol. 14, no. 3, pp. 213–220, 2000.

[163] B. G. Xiao, W. H. Zhu, and C. Z. Lu, "The presence of GM-CSF and IL-4 interferes with effect of TGF-beta on antigen presenting cells in patients with multiple sclerosis and in rats with experimental autoimmune encephalomyelitis," Cellular Immunology, vol. 249, no. 1, pp. 30–36, 2007.

[164] A. C. Melton, S. L. Bailey-Bucktrout, M. A. Travis, B. T. Fife, J. A. Bluestone, and D. Sheppard, "Expression of αvβ8 integrin on dendritic cells regulates Th17 cell development and experimental autoimmune encephalomyelitis in mice," The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4436–4444, 2010.

[165] M. Acharya, S. Mukhopadhyay, H. Paidassi et al., "αv Integrin expression by DCs is required for Th17 cell differentiation and development of experimental autoimmune encephalomyelitis in mice," The Journal of Clinical Investigation, vol. 120, no. 12, pp. 4445–4452, 2010.

[166] C. L. Langrish, Y. Chen, W. M. Blumenstock et al., "IL-23 drives a pathogenic T cell population that induces autoimmune inflammation," The Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005.

[167] Y. Komiyama, S. Nakae, T. Matsuki et al., "IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis," Journal of Immunology, vol. 177, no. 1, pp. 566–573, 2006.

[168] H. H. Hofstetter, S. M. Ibrahim, D. Koczan et al., "Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis," Cellular Immunology, vol. 237, no. 2, pp. 123–130, 2005.

[169] S. Haak, A. L. Croxford, K. Kreymborg et al., "IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice," Journal of Clinical Investigation, vol. 119, no. 1, pp. 61–69, 2009.

[170] B. Becher and B. M. Segal, "Th17 cytokines in autoimmune neuro-inflammation," Current Opinion in Immunology, vol. 23, no. 6, pp. 707–712, 2011.

[171] K. Kreymborg, R. Etzensperger, L. Dumoutier et al., "IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis," The Journal of Immunology, vol. 179, no. 12, pp. 8098–8104, 2007.

[172] J. M. Coquet, S. Chakravarti, M. J. Smyth, and D. I. Godfrey, "Cutting edge: IL-21 is not essential for Th17 differentiation or experimental autoimmune encephalomyelitis," The Journal of Immunology, vol. 180, no. 11, pp. 7097–7101, 2008.

[173] I. Sonderegger, J. Kisielow, R. Meier, C. King, and M. Kopf, "IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo," European Journal of Immunology, vol. 38, no. 7, pp. 1833–1838, 2008.

[174] B. Almolda, M. Costa, M. Montoya, B. González, and B. Castelano, "Increase in Th17 and t-reg lymphocytes and decrease of i22 correlate with the recovery phase of acute eae in rat," PLoS ONE, vol. 6, no. 2, Article ID e27473, 2011.

[175] W. Xu, Y. R. Li, Y. Dai et al., "IL-22 secreting CD4+ T cells in the patients with neuromyelitis optica and multiple sclerosis," Journal of Neuroimmunology, vol. 261, no. 1-2, pp. 87–91, 2013.

[176] C. Sutton, C. Brereton, B. Keogh, K. H. G. Mills, and E. C. Lavelle, "A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis," Journal of Experimental Medicine, vol. 203, no. 7, pp. 1685–1691, 2006.

[177] Q. Li, N. Powell, H. Zhang et al., "Endothelial IL-1RI is a critical mediator of EAE pathogenesis," Brain, Behavior, and Immunity, vol. 25, no. 1, pp. 160–167, 2011.

[178] B. Cannella and C. S. Raine, "The adhesion molecule and cytokine profile of multiple sclerosis lesions," Annals of Neurology, vol. 37, no. 4, pp. 424–435, 1995.

[179] M. El-Behi, B. Ciric, H. Dai et al., "The encephalitogenicity of Tg17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF," Nature Immunology, vol. 12, no. 6, pp. 568–575, 2011.

[180] L. Codarri, G. Gylvészii, V. Tosevski et al., "RORγt3 drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation," Nature Immunology, vol. 12, no. 6, pp. 560–567, 2011.
[181] I. L. King, M. A. Kroenke, and B. M. Segal, “GM-CSF-dependent, CD103$^+$ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization,” *Journal of Experimental Medicine*, vol. 207, no. 5, pp. 953–961, 2010.

[182] M. Grell, H. Wajant, G. Zimmermann, and P. Scheurich, “The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 2, pp. 570–575, 1998.

[183] N. H. Ruddle, C. M. Bergman, K. M. McGrath et al., “An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis,” *The Journal of Experimental Medicine*, vol. 172, no. 4, pp. 1193–1200, 1990.

[184] G. C. Suvannavejh, H. O. Lee, J. Padilla, M. C. Dal Canto, T. A. Barrett, and S. D. Miller, “Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG35-55-induced experimental autoimmune encephalomyelitis,” *Cellular Immunology*, vol. 205, no. 1, pp. 24–33, 2000.

[185] H. Körner, F. A. Lemckert, G. Chaudhri, S. Etteldorf, and J. D. Sedgwick, “Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system,” *European Journal of Immunology*, vol. 27, no. 8, pp. 1973–1981, 1997.

[186] A. Caminero, M. Comabella, and X. Montalban, “Tumor necrosis factor alpha (TNF-$\alpha$), anti-TNF-$\alpha$ and demyelination revisited: an ongoing story,” *Journal of Neuroimmunology*, vol. 234, no. 1-2, pp. 1–6, 2011.

[187] B. W. Van Oosten, F. Barkhof, L. Truyen et al., “Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody CA2,” *Neurology*, vol. 47, no. 6, pp. 1531–1534, 1996.

[188] S. Serada, M. Fujimoto, M. Mihara et al., “IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 26, pp. 9041–9046, 2008.

[189] M. D. Leech, T. A. Barr, D. G. Turner et al., “Cutting edge: IL-6-Dependent autoimmune disease: dendritic cells as a sufficient, but transient, source,” *Journal of Immunology*, vol. 190, no. 3, pp. 881–885, 2013.

[190] D. Mainone, G. C. Guazzi, and P. Annunziata, “IL-6 detection in multiple sclerosis brain,” *Journal of the Neurological Sciences*, vol. 146, no. 1, pp. 59–65, 1997.

[191] B. C. Kieseier, O. Storge, T. Dehmel et al., “Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses,” *JAMA Neurology*, vol. 70, no. 3, pp. 390–393, 2013.

[192] M. Menges, S. Rößner, C. Voigtländer et al., “Repetitive injections of dendritic cells matured with tumor necrosis factor $\alpha$ induce antigen-specific protection of mice from autoimmunity,” *The Journal of Experimental Medicine*, vol. 195, no. 1, pp. 15–21, 2002.

[193] S. Hirata, S. Senju, H. Matsuyoshi, D. Fukuma, Y. Uemura, and Y. Nishimura, “Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand 1,” *Journal of Immunology*, vol. 174, no. 4, pp. 1888–1897, 2005.

[194] F. Zhou, B. Ciric, G.-X. Zhang, and A. Rostami, “Immune therapy using lipopolysaccharide-stimulated bone marrow-derived dendritic cells to treat experimental autoimmune encephalomyelitis,” *Immunology and Cell Biology*, vol. 92, no. 2, pp. 124–132, 2014.

[195] F. Zhou, E. Lauretti, A. di Meco et al., “Intravenous transfer of apoptotic cell-treated dendritic cells leads to immune tolerance by blocking Th17 cell activity,” *Immunobiology*, vol. 218, no. 8, pp. 1069–1076, 2013.

[196] M. Isaksson, B. Ardesjö, L. Rönnblom et al., “Plasmacytoid DC promote priming of autoimmune Th17 cells and EAE,” *European Journal of Immunology*, vol. 39, no. 10, pp. 2925–2935, 2009.